3 Min Read
(Reuters) - Bio-Rad Laboratories has settled its patent infringement claims against French biotech company Stilla Technologies three days after the start of a trial in Boston federal court, according to a court filing.
A seal hangs over a building at Harvard University in Cambridge, Massachusetts. REUTERS/Jessica Rinaldi
The trial -- over Stilla’s alleged infringement of patents owned by Bio-Rad, Harvard University and others related to microfluidic genetic analysis technology -- began June 30, and the parties informed the court of the settlement July 3, according to a Wednesday order.
Details of the settlement weren’t immediately available.
Bio-Rad, Stilla, and Stilla’s attorney Juanita Brooks of Fish & Richardson didn’t immediately respond to a request for comment. Bio-Rad’s attorney Ed Reines of Weil Gotshal & Manges declined to comment.